Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
40-week open-label extension study of bifeprunox in schizophrenia
2004-000707-18Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bifeprunox in schizophrenia, sponsored by Lundbeck. Started Jun 2005; status: completed.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2004-000707-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000707-18.